Evolution of and perspectives on therapeutic approaches to nerve agent poisoning

Toxicology Letters

Volumn 206, Issue 1, 2011, Pages 5-13

  Masson, Patrick ^a,b,c  

^a CENTRE DE RECHERCHES   (France)

^b INSTITUT DE BIOLOGIE STRUCTURALE   (France)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Medical countermeasures; Nerve agent; Organophosphate poisoning; Pesticide; Prophylaxis; Treatment

Indexed keywords

1 (4 CARBAMOYLPYRIDINIO) 1' (2 HYDROXYIMINOMETHYLPYRIDINIO)DIMETHYL ETHER; ACETYLCHOLINESTERASE; ATROPINE; AVIZAFONE; BENZODIAZEPINE; BIS(PYRIDINIUM OXIME) DERIVATIVE; CARBAMIC ACID; CARBOXYLESTERASE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE; CHOLINESTERASE REACTIVATOR; DIAZEPAM; DONEPEZIL; GACYCLIDINE; GALANTAMINE; GLYCOPYRRONIUM BROMIDE; HUPERZINE A; KETAMINE; MACROGOL; MIDAZOLAM; NERVE AGENT; ORGANOPHOSPHORUS COMPOUND; OXIME DERIVATIVE; PYRIDOSTIGMINE; RIVASTIGMINE; SCAVENGER; SCOPOLAMINE; TACRINE; TEZAMPANEL; TOXIC SUBSTANCE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN DAMAGE; CELL THERAPY; DRUG DELIVERY SYSTEM; DRUG DETOXIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INTOXICATION; DRUG MEGADOSE; GENE THERAPY; HEMODIAFILTRATION; HUMAN; LIVER TOXICITY; MUTAGENESIS; NERVE AGENT POISONING; NEUROPATHY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT; SWEATING;

ANTIDOTES; BIOCATALYSIS; CHEMICAL WARFARE AGENTS; CHOLINESTERASE REACTIVATORS; GENE THERAPY; HUMANS; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; ORGANOPHOSPHORUS COMPOUNDS;

EID: 80051822924     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2011.04.006     Document Type: Article

References (161)

1. Aas P. Future considerations for the medical management of nerve-agent intoxication. Prehospital Disaster Med. 2003, 18:208-216.
2. Abbaba C., Rousseau J.M., Lelievre B., Turcant A., Lallement G., Ferec S., Bardot I., Diquet B. Pharmacokinetics analysis of pralidoxime after its intramuscular injection alone or in combination with atropine-avizafone in healthy volunteers. Br. J. Pharmacol. 2010, 161:1857-1867.
3. Allaste A.A., Lagerspetz M. Drugs and doublethink in marginalised communities. Crit. Criminol. 2005, 13:267-285.
4. Albuquerque E.X., Pereira E.F.R., Aracava Y., Fawcette W.P., Oliveira M., Randall W.R., Hamilton T.A., Kan R.K., Romano J.A., Adler M. Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:13220-13225.
5. Amourette C., Lamproglou I., Barbier L., Fauquette W., Zoppe A., Viret R., Diserbo M. Gulf war illness: effects of repeated stress and pyridostigmine treatment on blood-brain barrier permeability and cholinesterase in rat brain. Behav. Brain Res. 2009, 203:207-214.
6. Antonijevic B., Stojiljkovic M.P. Unequal efficacy of pyridium oximes in acute organophosphate poisoning. Clin. Med. Res. 2007, 5:71-82.
7. Aracava Y., Pereira E.F., Akkerman M., Adler M., Albuquerque E.X. Effectiveness of donepezil, rivastigmine, and (+/-)huperzine A in counteracting the acute toxicity of organophosphorus nerve agents: comparison with galantamine. J. Pharmacol. Exp. Ther. 2009, 331:1014-1024.
8. Arendse R., Irusen E. An atropine and glycopyrrolate combination reduces mortality in organophosphate poisoning. Hum. Exp. Toxicol. 2009, 28:715-720.
9. Ashani Y., Pistinner S. Estimation of the upper limit of human butyrylcholinesterase dose required for protection against organophosphates toxicity: a mathematically based toxicokinetic model. Toxicol. Sci. 2004, 77:358-367.
10. Aurbek N., Thiermann H., Eyer F., Eyer P., Worek F. Suitability of human butyrylcholinesterase as therapeutic marker and pseudo catalytic scavenger in organophosphate poisoning: a kinetic study. Toxicology 2009, 259:133-139.
11. Bajgar J. Organophosphates/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment. Adv. Clin. Chem. 2004, 38:151-216.
12. Bajgar J., Fusek J., Kassa J., Kuca K., Jun D. Chemical aspects of pharmacological prophylaxis against nerve agent poisoning. Curr. Med. Chem. 2009, 16:2977-2986.
13. Balali-Mood M., Shariat M. Treatment of organophosphate poisoning. Experience of nerve agents and acute pesticide poisoning on the effect of oximes. J. Physiol. Paris 1998, 92:375-378.
14. Ben Abraham R., Rudick V., Weinbroum A.A. Practical guidelines for acute care of victims of bioterrorism: conventional injuries and concomitant nerve agent intoxication. Anesthesiology 2002, 97:989-1004.
15. Bhattacharjee A.K., Kuca K., Musilek K., Gordon R.K. In silico pharmacophore model for tabun-inhibited acetylcholinesterase reactivators: a study of their stereoelectronic properties. Chem. Res. Toxicol. 2010, 23:26-36.
16. Bird S.B., Sutherland T.D., Gresham C., Oakeshott J., Scott C., Eddleston M. OpdA, a bacterial organophosphorus hydrolase, prevents lethalithy in rats after poisoning with highly toxic organophosphorus pesticides. Toxicology 2008, 247:88-92.
17. Bird S.B., Dawson A., Ollis D. Enzymes and bioscavengers for prophylaxis and treatment of organophosphates poisoning. Front. Biosci. (Schol. Ed.). 2010, 2:209-2020.
18. Blazer D., Gray G.C., Hotopf M., Macfarlane G., Sim M., Smith T.C., Wessley S. Acetylcholinesterase inhibition and Gulf war illness: conclusions are not supported by independent reviews of the same evidence. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:E20.
19. Bloch-Shilderman E., Rabinovitz I., Egoz I., Raveh L., Allon N., Grauer E., Gilat E., Weissman B.A. Subchronic exposure to low-doses of nerve agent VX: physiological, behavioral, histopathological and neurochemical studies. Toxicol. Appl. Pharmacol. 2008, 231:17-23.
20. Blum M.M., Timperley C.M., Williams G.R., Thiermann H., Worek F. Inhibitory potency of human acetylcholinesterase and enzymatic hydrolysis of fluorogenic nerve agent mimics by human paraoxonase 1 and squid diisopropyl fluorophosphatase. Biochemistry 2008, 47:5216-5224.
21. Cannard K. The acute treatment of nerve agent exposure. J. Neurol. Sci. 2006, 249:86-94.
22. Carletti, E., Schopfer, L.M., Colletier, J.-P., Froment, M.-T., Nachon, F., Weik, M., Lockridge, O., Masson, P., 2011. Reaction of cresyl saligenin phosphate, the organophosphorus implicated in the aerotoxic syndrome, with human cholinesterases: mechanistic studies employing kinetics, mass spectrometry and X-ray structure analysis. Chem. Res. Toxicol., April 18 [Epub ahead of print].
23. Casida J.E., Quistad G.B. Organophosphate toxicity: safety aspects of non acetylcholinesterase secondary targets. Chem. Res. Toxicol. 2004, 17:983-998.
24. Chronman C., Cohen O., Mazor O., Ordentlich A., Raveh L., Velan B., Shafferman A. Next generation of OP-bioscavengers: a circulatory long-lived 4-PEG-hypolysine mutant of F338A-huAChE with optimal pharmacokinetics and pseudo-catalytic activity. Chem. Biol. Interact. 2010, 187:253-258.
25. Cohen O., Kronman C., Raveh L., Mazor O., Ordentlich A., Shafferman A. Comparison of polyethylene glycol-conjugated recombinant human acetylcholinesterase and serum human bytyrylcholinesterase as bioscavengers of organophosphate compounds. Mol. Pharmacol. 2006, 70:1121-1131.
26. Coleman B.R., Ratcliffe R.H., Oguntayo S.A., Shi X., Doctor B.P., Gordon R.K., Nambiar M.P. [+]-Huperzine A treatment protects against N-methyl-d-aspartate-induced seizure/status epilepticus in rats. Chem. Biol. Interact. 2008, 175:387-395.
27. Collombet J.-M., Four E., Burckhart M.-F., Masqueliez C., Bernabe D., Baubichon F., Herodin F., Lallement G. Effect of cytokine treatment on the neurogenesis process in the brain of soman-poisoned mice. Toxicology 2005, 210:9-23.
28. Collombet J.-M., Beracochea D., Liscia P., Pierard C., Lallement G., Filliat P. Long-term effects of cytokine treatment on cognitive behavioral recovery and neuronal regeneration in soman-poisoned mice. Behav. Brain Res. 2011, 221:261-270.
29. Costa L.G., Giordano G., Furlong C.E. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem. Pharmacol. 2011, 81:337-344.
30. de Koning M.C., Joosen M.J., Noort D., van Zuylen A., Tromp M.C. Peripheral site ligand-oxime conjugates: a novel concept towards reactivation of nerve agent-inhibited human acetylcholinesterase. Bioorg. Med. Chem. 2010, 19:588-594.
31. Demar J.C., Clarkson E.D., Ratcliffe R.H., Campbell A.J., Thangavelu S.G., Herdman C.A., Leader H., Schulz S.M., Marek E., Medynets M.A., Ku T.C., Evans S.A., Khan F.A., Owens R.R., Nambiar M.P., Gordon R.K. Pro-2-PAM therapy for central and peripheral cholinesterases. Chem. Biol. Interact. 2010, 187:191-198.
32. Dishovsky C., Pivovarov A., Benschop H. Medical treatment of intoxications and decontamination of chemical agents in the area of terrorist attack 2006, Springer, Dordrecht, xviii+p. 233.
33. DiTargiani R.C., Chandrasekaran L., Belinskaya T., Saxena A. In search of a catalytic bioscavenger for the prophylaxis of nerve agent toxicity. Chem. Biol. Interact. 2010, 187:349-354.
34. Dorandeu F., Carpentier P., Baubichon D., Four E., Bernabe D., Burkhart M.F., Lallement G. Efficacy of ketamine-atropine combination in the delayed treatment of soman-induced status epilepticus. Brain Res. 2005, 1051:164-175.
35. Dorandeu F., Baille V., Mikler J., Testylier G., Lallement G., Sawyer T., Carpentier P. Protective effects of S+ketamine and atropine against lethality and brain damage during soman-induced status epilepticus in guinea pigs. Toxicology 2007, 234:185-193.
36. Dorandeu F., Carpentier P., Baille V., Dhote F., Testylier G., Pernot F., Mion G., Rüttimann F., Lallement G. Field treatment of soman-induced self-sustaining status epilepticus. Are ketamine and other NMDA antagonists the only options?. The Neurochemical Consequences of Organophosphate Poisoning in the CNS 2010, 149-183. Transworld Research Network, Trivandrum, Kerala, India. L. Raveh, B.A. Weissman (Eds.).
37. Duysen E.G., Parikh K., Aleti V., Manne V., Lockridge O., Chilukuri N. Adenovirus-mediated human paraoxonase1 gene transfer to provide protection against the toxicity of the organophosphorus pesticide toxicant diazoxon. Gene Ther. 2011, 18:250-257.
38. Eckert S., Eyer P., Muckter H., Worek F. Kinetic analysis of the protection afforded by reversible inhibitors against irreversible inhibition of acetylcholinesterase by highly toxic organophosphorus compounds. Biochem. Pharmacol. 2006, 72:344-357.
39. Eckert S., Eyer P., Worek F. Reversible inhibition of acetylcholinesterase by carbamates or hyperzine A increases residual activity of the enzyme upon soman challenge. Toxicology 2007, 233:180-186.
40. Eddleston M., Buckley N.A., Eyer P., Dawson A.H. Management of acute organophosphorus pesticide poisoning. Lancet 2008, 371:597-607.
41. Ekstrom F., Hornberg A., Artursson E., Hammarstrom L.G., Schneider G., Pang Y.P. Structure of HI-6 sarin-acetylcholinesterase determined by X-ray crystallography and molecular dynamics simulation: reactivator mechanism and design. PloS One 2009, 4:e5957.
42. Eyer P. The role of oximes in the management of organophosphorus pesticide poisoning. Toxicol. Rev. 2003, 22:165-190.
43. Fairchild S.Z., Peterson M.W., Hamza A., Zhan C.G., Cerasoli D.M., Chang W.E. Computational characterization of how the VX nerve agent binds to human serum paraoxonase 1. J. Mol. Model. 2011, 17:97-109.
44. Figueiredo T.H., Qashu F., Apland J.P., Aroniadou-Anderjaska V., Souza A.P., Braga M.F.M. The GluK1 (GluR5) kainate/AMPA receptor antagonist LY293558 reduced soman-induced seizures and neuropathology. J. Pharm. Exp. Ther. 2011, 336:303-312.
45. Garcia G.E., Campbell A.J., Olson J., Moorad-Doctor D., Morthole V.I. Novel oximes as blood-brain barrier penetrating cholinesterase reactivators. Chem. Biol. Interact. 2010, 187:199-206.
46. Gaydess A., Duysen E., Li Y., Gilman V., Kabanov A., Lockridge O., Bronich T. Visualisation of exogenous delivery of nanoformulated butyrylcholinesterase to the central nervous system. Chem. Biol. Interact. 2010, 187:295-298.
47. Ghanem E., Raushel F.M. Detoxification of organophosphate nerve agents by bacterial phosphotriesterase. Toxicol. Appl. Pharmacol. 2005, 207:459-470.
48. Genovese R.F., Sun W., Johnson C.C., Ditargiani R.C., Doctor B.P., Saxena A. Safety of administration of human butyrylcholinesterase and its conjugates with soman or VX in rats. Basic Clin. Pharmacol. Toxicol. 2010, 106:428-434.
49. Geyer B.C., Kannan L., Garnaud P.E., Broomfield C.A., Cadieux C.L., Cherni I., Hodgins S.M., Kasten S.A., Kelley K., Kilbourne J., Oliver Z.P., Otto T.C., Puffenberger I., Reeves T.E., Robbins N., Woods R.R., Soreq H., Lenz D.E., Cerasoli D.M., Mor T.S. Plant-derived human butyrylcholinesterase, but not an organophosphorous-compound hydrolyzing variant thereof, protects rodents against nerve agents. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:20251-20256.
50. Golomb B.A. Acetylcholinesterase inhibitors and Gulf war illnesses. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:4295-4300.
51. Golomb, B.A., 2008b. Flawed challenge to " acetylcholinesterase inhibitors and Gulf war illnesses" Proc. Natl. Acad. Sci. U.S.A., 105, E53 and E94.
52. Gotthard G., Hiblot J., Elias M., Chabriere E. Crystallization and preliminary X-ray diffraction analysis of the hyperthermophilic Sulfolobus islandicus lactonase. Acta Crystallogr. Sect. F: Struct. Biol. Cryst. Commun. 2011, 67:354-357.
53. Grunwald J., Raveh L., Doctor B.P., Ashani Y. Huperzine A as a pretreatment candidate drug against nerve agent toxicity. Life Sci. 1994, 54:991-997.
54. Handbook of Toxicology of Chemical Warfare Agents 2009, Academic Press/Elsevier, Amsterdam, xviii+p. 1147. R.C. Gupta (Ed.).
55. Gupta R.D., Goldsmith M., Ashani Y., Simo Y., Mullokandov G., Bar H., Ben-David M., Leader H., Margalit R., Silman I., Sussman J.L., Tawfik D.S. Directed evolution of hydrolases for prevention of G-type nerve agent intoxication. Nat. Chem. Biol. 2011, 510:120-125.
56. Harel M., Aharoni A., Gaidukov L., Brumshtein B., Khersonsky O., Meged R., Dvir H., Ravelli R.B., McCarthy A., Toker L., Silman I., Sussman J.L., Tawfik D.S. Structure and evolution of the serum paraoxonase family of detoxifying and antiatherosclerotic enzymes. Nat. Struct. Mol. Biol. 2004, 11:412-419.
57. Hemmert A.C., Otto T.C., Wierdi M., Edwards C.C., Fleming C.D., MacDonald M., Cashman J.R., Potter P.M., Cerasoli D.M., Redinbo M.R. Human carboxylesterase 1 stereoselectivity bind nerve agent cyclosarin and spontaneously hydrolyzes the nerve agent sarin. Mol. Pharmacol. 2010, 77:508-516.
58. Hornberg A., Artursson E., Warme R., Pang Y.P., Ekstrom F. Crystal structure of oxime-bound fenamiphos-acetylcholinesterases: reactivation involving flipping of the His447 ring to form a reactive Glu334-His447-oxime triad. Biochem. Pharmacol. 2010, 79:507-515.
59. Huang Y.J., Lundy P.M., Lazaris A., Huang Y., Baldassarre H., Wang B., Turcotte C., Côté M., Bellemare A., Bilodeau A.S., Brouillard S., Touati M., Herskovits P., Bégin I., Neveu N., Brochu E., Pierson J., Hockley D.K., Cerasoli D.M., Lenz D.E., Wilgus H., Karatzas C.N., Langermann S. Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin. BCM Biotechnol. 2007, 8(50):11.
60. Huang Y.J., Huang Y., Baldassarre H., Wang B., Lazaris A., Leduc M., Bilodeau A.S., Bellemare A., Côté M., Herskovits P., Touati M., Turcotte C., Valeanu L., Lemée N., Wilgus H., Bégin I., Bhatia B., Rao K., Neveu N., Brochu E., Pierson J., Hockley D.K., Cerasoli D.M., Lenz D.E., Karatzas C.N., Langermann S. Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning. Proc. Natl. Acad. Sci. U.S.A. 2008, 104:13603-13608.
61. Husain K., Ansari R.A., Ferder L. Pharmacological agents in the prophylaxis/treatment of organophosphorous pesticide intoxication. Indian Exp. Biol. 2010, 48:642-650.
62. Jackson C.J., Scott C., Carville A., Mansfield K., Ollis S.L., Bird S.B. Pharmacokinetics of OpdA, an organophosphorus hydrolase, in the African green monkey. Biochem. Pharmacol. 2010, 80:1075-1079.
63. Jokanovic M. Current understanding of the mechanisms involved in metabolic detoxification of warfare agents. Toxicol. Lett. 2009, 188:1-10.
64. Jokanovic M., Prostan M. Pyridinium oximes as cholinesterase reactivators. Structure-activity relationship and efficacy in the treatment of poisoning with organophosphorus compounds. Curr. Med. Chem. 2009, 16:2177-2188.
65. Jokanovic M., Kosanovic M., Brkic D., Vukomanovic P. Organophsophate induced delayed polyneuropathies in man: an overview. Clin. Neurol. Neurosurg. 2011, 113:7-10.
66. Joosen, M.J.A., Wortelboer, H.M., van Helden, H.P.M., 2011. Increasing oxime efficacy in the brain by blood brain barrier modulation. Toxicol. Lett., in this issue.
67. Jun D., Mucilova L., Link M., Loiodice M., Nachon F., Rochu D., Renault F., Masson P. Preparation and characterization of methoxy polyethylene glycol-conjugated phosphotriesterase as a potential catalytic bioscavenger against organophosphate poisoning. Chem. Biol. Interact. 2010, 187:380-383.
68. Kalisiak, J., Ralph, E.C., Zhang, J., Cashman, J.R., 2011. Amidine-oximes: reactivators for organophosphate exposure. J. Med. Chem., in press.
69. Kassa J., Krejcova G., Skopec F., Herink J., Bajgar J., Seveloca L., Tichy M., Pecka M. The influence of sarin on various physiological functions in rats following single or repeated low-level inhalation. Inhal. Toxicol. 2004, 16:517-530.
70. Kassa J., Krocova Z., Sevelova L., Sheshko V., Kasalova I., Neubauerova V. The influence of a single or repeated low-level sarin exposure on immune functions of inbred BALB/c mice. Basic Clin. Pharmacol. Toxicol. 2004, 94:139-143.
71. Kassa J. Therapeutic and neuroprotective efficacy of pharmacological pretreatment and antidotal treatment of acute tabun or soman poisoning with the emphasis on pretreatment drug PANPAL. Arh. Hig. Rada. Toksikol. 2006, 57:427-434.
72. Kassa J., Kuca K., Karasova J., Musilek K. The development of new oximes and the evaluation of their reactivating, therapeutic and neuroprotective efficacy against tabun. Mini. Rev. Med. Chem. 2008, 8:1134-1143.
73. Keeler J.R., Hurst C.G., Dunn M.A. Pyridostigmine used as a nerve agent pretreatment under wartime conditions. JAMA 1991, 266:693-695.
74. Kiderlen D., Worek F., Klimmek R., Eyer P. The phosphoryl oxime-destroying activity of human plasma. Arch. Toxicol. 2000, 74:27-32.
75. Koplovitz I., Schutz S. Perspective on the use of scopolamine as an adjunct treatment to enhance survival following organophosphorus nerve agent poisoning. Mil. Med. 2010, 175:878-882.
76. Kovach I.M. Stereochemistry and secondary reactions in the irreversible inhibition of serine hydrolases by organophosphorus compounds. J. Phys. Org. Chem. 2004, 17:602-614.
77. Kovarik Z., Radic Z., Berman H.A., Taylor P. Mutation of acetylcholinesterase to enhance oxime-assisted catalytic turnover of methylphosphonate. Toxicology 2007, 233:784-789.
78. Kovarik Z., Katalinic M., Sinko G., Binder J., Holas O., Jung Y.S., Musilova L., Jun D., Kuca K. Pseudo-catalytic scavenging: searching for a suitable reactivator of phosphorylated butyrylcholinesterase. Chem. Biol. Interact. 2010, 187:167-171.
79. Lallement G., Baubichon D., Clarencon D., Galonnier M., Peoch' M., Carpentier P. Review of the value of gacyclidine (GK-11) as adjuvant medication to conventional treatments of organophosphate poisoning: primate experiments mimicking various scenarios of military or terrorist attack by soman. Neurotoxicology 1999, 20:675-684.
80. Lallement G., Demoncheaux J.P., Foquin A., Baubichon D., Galonnier M., Clarencon D., Dorandeu F. Subchronic administration of pyridostigmine or huperzine to primates: compared efficacy against soman poisoning. Drug Chem. Toxicol. 2002, 25:309-320.
81. Layish I., Krivoy A., Rotman E., Finkelstein A., Tashma Z., Yehezkelli Y. Pharmacologic prophylaxis against nerve agent poisoning. Isr. Med. Assoc. J. 2005, 7:182-187.
82. Leader H., Wolfe A.D., Chiang P.K., Gordon R.K. Pyridophens: binary pyridostigmine-aprophen prodrugs with differential inhibition of acetylcholinesterase, butyrylcholinesterase, and muscarinic receptors. J. Med. Chem. 2002, 45:902-910.
83. Lenz D.E., Yeung D., Smith J.R., Sweeney R.E., Lumney L.A., Cerasoli D.M. Stoichiometric and catalytic scavengers as protection against nerve agent toxicity: a mini review. Toxicology 2007, 233:31-39.
84. Levy A., Kushnir M., Chapman S., Brandeis R., Teitelbaum Z., Gilat E. Characterization of early plasma concentration of midazolam in pigs after administration by an autoinjector. Drug Metab. Dispos. 2004, 25:297-301.
85. Li B., Sedlacek M., Manoharan I., Boopathy R., Duysen E.G., Masson P., Lockridge O. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem. Pharmacol. 2005, 70:1673-1684.
86. Li B., Nachon F., Froment M.T., Verdier L., Debouzy J.C., Brasme B., Gillon E., Schopfer L.M., Lockridge O., Masson P. Binding and hydrolysis of soman by human serum albumin. Chem. Res. Toxicol. 2008, 21:421-431.
87. Li S., Ip D.T., Liu J.M., Miao Y.G., Ke L.J., Wan D.C. High-level expression of functional recombinant human butyrylcholinesterase in silkworm larvae by bac-to-basic system. Chem. Biol. Interact. 2010, 197:349-354.
88. Linusson, A., Edvinson, L., Andersson, D., Hornberg, A., Artursson, E., Akfur, C., Ekstrom, F. In vitro screening of chemical libraries, crystallography and computational chemistry as a route to novel nerve agent antidotes. Toxicol. Lett., in this issue.
89. Lockridge O., Schopfer L.M. Review of tyrosine and lysine as new motifs for organophosphate binding to proteins that have no active site serine. Chem. Biol. Interact. 2010, 187:344-348.
90. Lundy P., Raveh L., Amitai G. Development of the bisquaternary oxime HI-6 toward clinical use in the treatment of organophosphate nerve agent poisoning. Toxicol. Rev. 2006, 25:231-243.
91. Luo C., Saxena A., Smith M., Garcia G., Radic Z., Taylor P., Doctor B.P. Phosphoryl oxime inhibition of acetylcholinesterase during oxime reactivation is prevented by edrophonium. Biochemistry 1999, 38:9937-9947.
92. Lushchekina, S., Masson, P., Nachon, F., Nemukhin, A.V., Varfolomeev, S.D., 2011. QM/MM modeling of the G117H butyrylcholinesterase catalyzed echothiophate hydrolysis reaction mechanism. Poster at the 13th MCDC, Munich, 13-14th April 2011.
93. Maxwell D.M., Brecht K.M. Carboxylesterase: specificity and spontaneous reactivation of an endogenous scavenger for organophsophorus compounds. J. Appl. Toxicol. 2001, 21(Suppl. 1):S103-S107.
94. Maxwell D.M., Brecht K.M., Koplovitz I.M., Sweeney R.E. Acetylcholinesterase inhibition: does it explain the toxicity of organophosphorus compounds?. Arch. Toxicol. 2006, 80:756-760.
95. Masson P., Nachon F., Broomfield C.A., Lenz D.E., Verdier L., Schopfer L.M., Lockridge O. A collaborative endeavour to design cholinesterase-based catalytic scavengers against toxic organophosphorus esters. Chem. Biol. Interact. 2008, 175:273-280.
96. Masson P., Rochu D. Catalytic bioscavengers against toxic esters, an alternative approach for prophylaxis and treatments of poisonings. Acta Nat. 2009, 1:68-78.
97. Masson P., Lockridge O. Butyrylcholinesterase for protection from organophosphorus poisons: catalytic complexity and hysteretic behavior. Arch. Biochem. Biophys. 2010, 494:107-120.
98. Masson P., Nachon F., Lockridge O. Structural approach to the aging of phosphylated cholinesterases. Chem. Biol. Interact. 2010, 187:157-162.
99. McDonough J.H., McMonagle J.D., Shih T.-M. Time-dependent reduction in the anticonvulsant effectiveness of diazepam against soman-induced seizures in guinea pigs. Drug Chem. Toxicol. 2010, 33:279-283.
100. McDonough, J., Kan, R., Myers, T., Capacio, B., Shih, T.-M., Koplovitz, I., 2011. Prevention of the neurobehavioral consequences of nerve agent exposure by oximes that cross the blood brain barrier. Toxicol. Lett., in this issue.
101. Melzer M., Chen J.C., Heidenreich A., Gab J., Koller M., Kehe K., Blum M.M. Reversed enantioselectivity of diisopropyl fluorophosphatase against organophosphorus nerve agents by rational design. J. Am. Chem. Soc. 2009, 131:17226-17232.
102. Mercey G., Verdelet T., Saint-Andre G., Gillon E., Wagner A., Baati R., Jean L., Nachon F., Renard P.-Y. First efficient uncharged reactivators for the dephosphorylation of poisoned human acetylcholinesterase. Chem. Commun. 2011, 47:5295-5297.
103. Merone L., Mandrich L., Porzo E., Rossi M., Muller S., Reiter G., Worek F., Manco G. Improving the promiscuous nerve agent hydrolase activity of a thermostable archaeal lactonase. Bioresour. Technol. 2010, 10:9204-9212.
104. Meshulam Y., Cohen G., Chapman S., Alkalai D., Levy A. Prophylaxis against organophosphate poisoning by sustained release of scopolamine and physostigmine. J. Appl. Toxicol. 2001, 21(Suppl. 1):S75-S78.
105. Monov, A, Dishovsky, C., (Eds.), 2005. Medical Aspects of Chemical and Biological Terrorism. Publishing House of the Union of Scientists of Bulgaria, Sofia, p. 354.
106. Myers T.M., Sun W., Saxena A., Doctor B.P., Bonvillain A.J., Clark M.G. Systemic administration of the potential countermeasure huperzine reversibly inhibits central and peripheral acetylcholinesterase activity without adverse cognitive-behavioral effects. Pharmacol. Biochem. Behav. 2010, 94:477-481.
107. Nachon F., Carletti E., Wandhammer M., Nicolet Y., Schopfer L.M., Masson P., Lockridge O. X-ray crystallographic snapshots of reaction intermediates in the G117H mutant of human butyrylcholinesterase, a nerve agent target engineered into a catalytic bioscavenger. Biochem. J. 2011, 434:73-82.
108. Institut toksikologhi 75 let (in Russian) 2010, Saint Petersburg, Elbi-SPb, p. 160. S.P. Nechiporenko, A.N. Petrov (Eds.).
109. Ordentlich A., Barak D., Kronman C., Benschop H.P., De Jong L.P.A., Ariel N., Barak R., Segall Y., Velan B., Shafferman A. Exploring the active center of human acetylcholinesterase with stereomers of an organophosphorus inhibitor with two chiral centers. Biochemistry 1999, 38:3055-3066.
110. Okumara T., Hisaoka T., Yamada A., Naito T., Isonuma H., Okumura S., Miura K., Sakurada M., Maekawa H., Ishimatsu S., Takasu N., Suzuki K. The Tokyo subway sarin attack: lessons learned. Toxicol. Appl. Pharmacol. 2005, 207:471-476.
111. Otto T.C., Harsch C.K., Yeung D.T., Magliery T.J., Cerasoli D.M., Lenz D.E. Dramatic differences in organophosphorus hydrolase activity between human and chimeric recombinant mammalian paraoxonase-1 enzymes. Biochemistry 2009, 48:10416-10422.
112. Otto T.C., Kasten S.A., Kovaleva E., Liu Z., Buchman G., Tolosa M., Davis D., Smith J.R., Belcerzak R., Lenz D.E., Cerasoli D.M. Purification and characterization of functional human paraoxonase-1 expressed in Trichoplusia ni larvae. Chem. Biol. Interact. 2010, 187:388-392.
113. Parikh K., Duysen E.G., Snow B., Jensen N.S., Manne V., Lockridge O., Chilukuri N. Gene-delivery butyrylcholinesterase is prophylactic against the toxicity of chemical warfare nerve agents and organophosphorus compounds. J. Pharmacol. Exp. Ther. 2011, 337:92-101.
114. Pereira J., Aracava Y., Alkondon M., Akkerman M., Merchenthaler I., Albuquerque E.X. Molecular and cellular actions of galantamine: clinical implications for treatment of organophosphorus poisoning. J. Mol. Neurosci. 2010, 40:196-203.
115. Petrov A.N., Sofronov G.A., Nechiporenko S.P., Somin I.N. Antidoty phosphororganicheskikh otravliaiushchikh veshchestv [antidotes of organophosphate poisoning] (in Russian). Ros. Khim. Zh. XLVIII 2004, 110-116.
116. Piribi F., Kozikowski A.P., Pinna G., Auta J., Kadriu B., Costa E., Guidotti A. The combination of huperzine A and imidazenil is an effective strategy to prevent diisopropyl fluorophosphate toxicity in mice. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:14169-14174.
117. Renault F., Carus T., Barraud C., Elias M., Chabriere E., Masson P., Rochu D. Integrative analytical approach by capillary electrophoresis under high pressure optimized for deciphering intrinsic and extrinsic cofactors that modulate activity and stability of paraoxonase. J. Chromatogr. B 2010, 878:1346-1355.
118. Research Advisory Committee on Gulf War Veterans' illnesses, 2008. Gulf war illness and the Health of Gulf War Veterans: Scientific Findings and Recommendations. US Government Printing Office, Washington, DC. iv+p. 454.
119. Rochu D., Chabrière E., Masson P. Human paraoxonase: a promising approach for pre-treatment and therapy of organophosphorus poisoning. Toxicology 2007, 233:47-59.
120. Romano, J.A., Luckey, B.J., Salem, H. (Eds.), 2008. Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics. xxv+p. 723.
121. Rosenberg Y.J., Saxena A., Sun W., Jiang X., Chilukuri N., Luo C., Doctor B.P., Lee K.D. Demonstration of in vivo stability and lack of immunogenicity of a polyethyleneglycol-conjugated recombinant CHO-derived butyrylcholinesterase bioscavenger using a homologous macaque model. Chem. Biol. Interact. 2010, 187:279-286.
122. Rousseau J.M., Besse-Bardot I., Franck L., Libert N., Lallement G., Clair P. Interet de la seringue Ineurope® devant une intoxication par neurotoxique de guerre [Interest of Ineurope® syringe for nerve agent intoxication]. Ann. Fr. Anesth. Réanim. 2009, 28:482-488.
123. Rustsenko, I.P., Serdiuk, O.O., 2008. [Drug abuse among young people of Kharkov: custom and habit] (in Ukrainian). In: Methodology, Theory and Practice of Modern Society Sociological Analysis, Zbirnik Naukovikh Prats' [Collect. Sci. Works], Univ d'Etat V.N. Karazin, Kharkov, pp. 538-542.
124. Sanson B., Nachon F., Colletier J.P., Froment M.T., Toker L., Greenblatt H.M., Sussman J.L., Ashani Y., Masson P., Silman I., Weik M. Crystallographic snapshots of nonaged and aged conjugates of soman with acetylcholinesterase, and of a ternary complex of the aged conjugate with pralidoxime. J. Med. Chem. 2009, 52:7593-7603.
125. Anticholinesterase Pesticides: Metabolism, Neurotoxicity, and Epidemiology. 2010, John Wiley & Sons, Hoboken, New Jersey, USA, xviii+p. 625. H. Satoh, R.C. Gupta (Eds.).
126. Saxena A., Tipparaju P., Luo C., Doctor B.P. Pilot-scale production of human serum butyrylcholinesterase suitable for use as a bioscavenger against nerve agent toxicity. Process. Biochem. 2010, 45:1313-1318.
127. Saxena A., Sun W., Fedorko J.M., Koplovitz I., Doctor B.P. Prophylaxis with human serum butyrylcholinesterase protects guinea pigs exposed to multiple lethal doses of soman or VX. Biochem. Pharmacol. 2011, 81:164-169.
128. Sheridan R.D., Smith A.P., Turner S.R., Tattersal J.E.H. Nicotinic antagonists in the treatment of nerve agent intoxication. J. Roy. Soc. Med. 2005, 98:114-115.
129. Shih D., Gu L., Xia Y.R., Navab M., Li W.F., Hama S., Castellani L.W., Furlong C.E., Costa L.G., Fogelman A.M., Lusis A.J. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998, 394:284-287.
130. Shih T.-M., Skovira J.W., O'Donnell J.C., McDonough J.H. In vivo reactivation by oximes of inhibited blood, brain and peripheral tissue cholinesterase activity following exposure to nerve agents in guinea pigs. Chem. Biol. Interact. 2010, 187:207-214.
131. Shih T.-M., Skovira J.W., O'Donnell J.C., McDonough J.H. Treatment with tertiary oximes prevents seizures and improves survival following sarin intoxication. J. Mol. Neurol. 2010, 40:63-69.
132. Schopfer L.M., Grigoryan H., Li B., Nachon F., Masson P., Lockridge O. Mass spectral characterization of organophosphate-labeled, tyrosine-containing peptides: characteristic mass fragments and a new binding motif for organophosphates. J. Chromatrogr. B 2010, 878:1297-1311.
133. Schopfer L.M., Furlong C.E., Lockridge O. Development of diagnostics in the search for an explanation of aerotoxic syndrome. Anal. Biochem. 2010, 404:64-74.
134. Skovira J.W., O'Donnell J.C., Koplovitz I., Kan R.K., McDonough J.H., Shih T.-M. Reactivation of brain acetylcholinesterase by monoisonitrosoacetone increases the therapeutic efficacy against nerve agents in guinea pigs. Chem. Biol. Interact. 2010, 187:318-324.
135. Sogorb M.A., Vilanova E., Carrera V. Future applications of phosphotriesterases in the prophylaxis and treatment of organophosphorus insecticide and nerve agent poisoning. Toxicol. Lett. 2004, 151:219-233.
136. Sogorb M.A., Vilanova E. Serum albumins and detoxication of anti-cholinesterase agents. Chem. Biol. Interact. 2010, 187:325-329.
137. Soukup O., Tobin G., Kumar U.K., Binder J., Proska J., Jun D., Fusek J., Kuca K. Interaction of nerve agent antidotes with cholinergic systems. Curr. Med. Chem. 2010, 17:1708-1718.
138. Stevens R.C., Suzuki S.M., Cole T.B., Oark S.S., Richter R.J., Furlong C.E. Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:12780-12784.
139. Sweeney R.E., Maxwell D.M. A theoretical expression for the protection associated with stoichiometric and catalytic scavengers in a single compartment model of organophosphate poisoning. Math. Biosci. 2003, 181:133-143.
140. Tattersall, J.E.H. Further strategy for treatment of nerve agent poisoning: nicotinic receptors. Toxicol. Lett., in this issue.
141. Terrier F., Rodriguez-Dafonte P., Le Gueval E., Moutiers G. Revisiting the reactivity of oximate α-nucleophiles with electrophilic phosphorus centers. Relevance to detoxification of sarin, soman and DFP under mild conditions. Org. Biomol. Chem. 2006, 4:4352-4363.
142. Thiermann H., Szinicz L., Eyer P., Felgenauer N., Zilker T., Worek F. Lessons to be learnt from organophosphate pesticide poisoning for the treatment of nerve agent poisoning. Toxicology 2007, 233:145-154.
143. Tochigi M., Umekage T., Otani T., Kato T., Iwanami A., Asukai N., Sasaki T., Kato N. Serum cholesterol, uric acid and cholinesterase in victims of the Tokyo subway sarin poisoning: a relation with post-traumatic disorder. Neurosci. Res. 2002, 44:267-272.
144. Tonev, S., Kanev, K., Dishovsky, C. (Eds.), 2010. Medical management of chemical and biological casualties. J. Med. CBR, 10, 360. On line: http://www.jmedcbr.org/issue_0801/Dishovsky/Medical_Mgt_of_CB_Casualties.pdf.
145. Tsai P.-C., Bigley A., Li Y., Ghanem E., Cadieux C.L., Kasten S.A., Reeves T.E., Cerasoli D.M., Raushel F.M. Stereoselective hydrolysis of organophosphate nerve agents by the bacterial phosphotriesterase. Biochemistry 2010, 49:7978-7987.
146. Valiyaveettil M., Alamneh Y., Biggemann L., Soojhawon I., Doctor B.P., Nambiar M.P. Efficient hydrolysis of the chemical warfare nerve agent tabun by recombinant and purified human and rabbit serum paraoxonase 1. Biochem. Biophys. Res. Commun. 2010, 403:97-102.
147. Valiyaveettil M., Alamneh Y., Rezk P., Biggemann L., Perkins M., Sciuto A.M., Doctor B.P., Nambiar M.P. Protective efficacy of catalytic bioscavenger, paraoxonase 1 against sarin and soman exposure in guinea pigs. Biochem. Pharmacol. 2011, 81:800-809.
148. Vayron P., Renard P.Y., Taran F., Creminon C., Frobert Y., Grassi J., Mioskowski C. Toward antibody-catalyzed hydrolysis of organophosphorus poisons. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:7058-7063.
149. Voicu V.A., Thiermann H., Radulescu F.S., Mircioiu C., Miron D.S. The toxicokinetics and toxicodynamics of organophosphates versus the pharmacokinetics and pharmacodynamics of oximes antidotes: biological consequences. Basic Clin. Pharmacol. Toxicol. 2010, 106:73-85.
150. Vyas N.K., Nickitenko A., Rastogi V.K., Shah S.S., Quiocho F.A. Structural insight into the dual activities of the nerve agent degrading organophosphate anhydrolase/prolidase. Biochemistry 2010, 26:547-559.
151. Wandhammer M., Carletti E., van der Schans M., Gillon E., Nicolet Y., Masson P., Goeldner M., Noort D., Nachon F. Structural study of the complex stereoselectivity of human butyrylcholinesterase for the neurotoxic V-agents. J. Biol. Chem. 2011, 286:16783-16789.
152. Weissman B.A., Raveh L. Therapy against organophosphate poisoning: the importance of anticholinergic drugs with antiglutamatergic properties. Toxicol. Appl. Pharmacol. 2008, 232:351-358.
153. Wetherell J., Hall T., Passingham S. Physostigmine and hyoscine improves protection against the lethal and incapacitating effects of nerve agent poisoning in the guinea-pig. Neurotoxicology 2002, 23:341-349.
154. Wetherell J., Price M., Munford H., Armstrong S., Scott L. Development of next generation medical countermeasures to nerve agent poisoning. Toxicology 2007, 233:120-127.
155. Wille T., Ekstrom F., Lee J.C., Pang Y.P., Thiermann H., Worek F. Kinetics analysis of interactions between alkylene-linked bis-pyrimidiumaldoximes and human acetylcholinesterases inhibited by various organophosphorus compounds. Biochem. Pharmacol. 2010, 80:941-946.
156. Wille, T., Thiermann, H., Worek, F. In vitro kinetic interactions of DEET, pyridostigmine and organophosphus pesticides with human acetylcholinesterase. Chem. Biol. Interact., in press.
157. Worek F., Eyer P., Aurbek N., Szinicz L., Thiermann H. Recent advances in evaluation of oxime efficacy in nerve agent poisoning by in vitro analysis. Toxicol. Appl. Pharmacol. 2007, 219:226-234.
158. Worek F., Aurbek N., Wille T., Eyer P., Thiermann H. Kinetic prerequisite of oximes reactivators of phosphate-inhibited acetylcholinesterase: a theoretical approach. J. Enzyme Inhib. Med. Chem. 2011, 26:303-308.
159. Yanagisawa N., Morita H., Nakajima T. Sarin experience in Japan: acute toxicity and long-term effects. J. Neurol. Sci. 2006, 249:76-85.
160. Yeung D.T., Smith J.R., Sweeney R.E., Lenz D.E., Cerasoli D.M. A gas chromatographic-mass spectrometric approach to examining stereoselective interaction of human plasma proteins with soman. J. Anal. Toxicol. 2008, 32:86-91.
161. Yokoyama K. Blood purification for severe sarin poisoning after the Tokyo subway attack. J. Am. Med. Assoc. 1995, 274:379.